Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (1-10 of 518) with videos related to

Pageof 52
Sort By:
Seminars in Hematology|May 16, 2018
MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical ToolOla Landgren
Lakartidningen|May 7, 2002
[Medical IT progress in American health care]Ola Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2013
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategiesOla Landgren
Leukemia|May 5, 2026
Smoldering multiple myeloma in transition: redefining early myeloma in the modern eraOla Landgren
Blood|August 13, 2011
Sun, mother of life, prevents cancerOla Landgren
Blood|October 24, 2015
No CLL transmission through blood transfusionOla Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2017
Shall we treat smoldering multiple myeloma in the near future?Ola Landgren
Seminars in Hematology|January 15, 2011
Multiple myeloma precursor disease: current clinical dilemma and future opportunitiesOla Landgren
Hematology. American Society of Hematology. Education Program|January 18, 2011
Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiologyOla Landgren
Blood|October 14, 2017
Racial/ethnic disparities: need more work!Ola Landgren
Pageof 52

Showing results (1-10 of 518) with videos related to

Sort By:
Pageof 52
Seminars in Hematology|May 16, 2018
MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical ToolOla Landgren
Lakartidningen|May 7, 2002
[Medical IT progress in American health care]Ola Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2013
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategiesOla Landgren
Leukemia|May 5, 2026
Smoldering multiple myeloma in transition: redefining early myeloma in the modern eraOla Landgren
Blood|August 13, 2011
Sun, mother of life, prevents cancerOla Landgren
Blood|October 24, 2015
No CLL transmission through blood transfusionOla Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2017
Shall we treat smoldering multiple myeloma in the near future?Ola Landgren
Seminars in Hematology|January 15, 2011
Multiple myeloma precursor disease: current clinical dilemma and future opportunitiesOla Landgren
Hematology. American Society of Hematology. Education Program|January 18, 2011
Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiologyOla Landgren
Blood|October 14, 2017
Racial/ethnic disparities: need more work!Ola Landgren
Pageof 52